Boost.ai Named as a Challenger in 2023 Gartner® Magic Quadrant™ for Enterprise Conversational AI Platforms
Boost.ai, a leading conversational AI platform, today announced it has been recognized as a Challenger by Gartner in their 2023 Magic Quadrant for Enterprise Conversational AI Platforms. For the second consecutive year, Boost.ai has been recognized in this Magic Quadrant by Gartner for its Ability to Execute and Completeness of Vision. We believe being recognized as a Challenger reinforces the company’s strength and leadership within the conversational AI space, as it continues to expand its technology and support a growing roster of clients across the globe.
The report states that “Gartner defines the enterprise conversational AI platform market as the market for software platforms used to build, orchestrate, and maintain multiple use cases of modalities of conversational automation.” As expectations for quality customer service continue to rise globally, Boost.ai has refined its technology, deploying industry-leading virtual agents that scale to meet the requirements of enterprise organizations. Boost.ai’s solution is powered by conversational AI, and the platform allows customers to scale up individually to thousands of industry-specific intents, enabling these businesses to effectively manage a very broad scope of customer queries in a matter of weeks in virtually any industry. With consistent 90% resolution rates, the solution facilitates immediate responses with accuracy, while its no-code conversation builder and AI trainer program allow customers to self-service their virtual agents and easily deploy service flows in response to customer feedback.
“Customer experience and digital transformation continue to be a priority, and I’m proud to say we have executed on this priority at Boost.ai. Over the last year, we’ve set customers up for success with our easily adaptable and scalable technology, and have solidified ourselves as world leaders in delivering the best possible customer experience for clients,” said Jerry Haywood, CEO of Boost.ai. “From my perspective, our placement in the 2023 Gartner Magic Quadrant is a testament to the work our team has done to perfect our solution and expand our existing offers based on new trends and technology.”
We believe this latest Magic Quadrant report encapsulates a strong previous year for Boost.ai, in which the company announced multiple customer wins and partnerships in the US and UK including Aspire Insurance, Metrobank, CallMiner, and Clarasys. The company also appointed Jerry Haywood as the new CEO, bringing 20 years of enterprise technology experience. With a conversational AI platform that delivers unlimited scalability as its central offering, Boost.ai is now leveraging its technology to tackle a new AI frontier: large language models (LLMs). Boost.ai combines the generative capabilities of LLMs like GPT-3, with company data to optimize their virtual agents for improved accuracy and brand alignment. As these models continue to develop, Boost.ai is working to ensure the technology can be properly integrated to offer the most advanced enterprise solution possible for both chat and voice.
"It’s an exciting time to be in the conversational AI space as the technology has taken another leap forward with the recent advancement of powerful LLMs. We think Future Gartner Magic Quadrant reports in this category could very well be defined by how well providers respond to this trend. We’re confident that we’re integrating the tech in a way that increases efficiency and performance, but most importantly is brand safe for our customers," said Lars Ropeid Selsås, Founder of Boost.ai. “I'm excited to see the massive amount of improvement our team and solution made in just one year, and now we can set our sights on solidifying our position in the market even further."
Boost.ai continues its upward global trajectory within the Enterprise Conversational AI market. The Boost.ai platform will focus on continuing to innovate and stay at the forefront of helping enterprise organizations to deliver exceptional customer experiences.
To learn more about how Boost.ai is empowering customers like DNB and Aspire Insurance using conversational AI, please visit: https://www.boost.ai/.
Gartner Disclaimer:
GARTNER is a registered trademark and service mark of Gartner Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005516/en/
Contact information
Jon Burch
Boost.ai@resonancecrowd.com
+44 208 819 3170
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
